The estimated Net Worth of Daniel V Meyaard is at least $2.16 Million dollars as of 14 February 2013. Daniel Meyaard owns over 304 units of Idexx Laboratories stock worth over $2,164,988 and over the last 15 years Daniel sold IDXX stock worth over $0.
Sign up
Daniel Meyaard IDXX stock SEC Form 4 insiders trading
Daniel has made over 4 trades of the Idexx Laboratories stock since 2011, according to the Form 4 filled with the SEC. Most recently Daniel exercised 304 units of IDXX stock worth $149,039 on 14 February 2013.
The largest trade Daniel's ever made was exercising 810 units of Idexx Laboratories stock on 1 September 2012 worth over $397,111. On average, Daniel trades about 298 units every 76 days since 2010. As of 14 February 2013 Daniel still owns at least 4,416 units of Idexx Laboratories stock.
You can see the complete history of Daniel Meyaard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Daniel Meyaard's mailing address?
Daniel's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Insiders trading at Idexx Laboratories
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers, and Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
What does Idexx Laboratories do?
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
What does Idexx Laboratories's logo look like?
Complete history of Daniel Meyaard stock trades at Idexx Laboratories
Idexx Laboratories executives and stock owners
Idexx Laboratories executives and other stock owners filed with the SEC include:
-
Jonathan Ayers,
Director -
Jonathan Mazelsky,
President, Chief Executive Officer, Director -
Brian McKeon,
Chief Financial Officer, Executive Vice President, Treasurer -
Kathy Turner,
Corporate Vice President and Chief Marketing Officer -
Jonathan J. Mazelsky,
Pres, CEO & Director -
Sharon Underberg,
Corporate Vice President, General Counsel, and Corporate Secretary -
Michael Lane,
Executive Vice President, General Manager, Reference Laboratories and Information Technology -
Brian P. McKeon,
CFO, Exec. VP & Treasurer -
Giovani Twigge,
Chief Human Resource Officer, Corporate Vice President -
Dr. Nimrata Khatra Hunt P.E., Ph.D.,
Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations -
Michael J. Lane,
Exec. VP and GM of Reference Laboratories & Information Technology -
James F. Polewaczyk,
Exec. VP & Chief Commercial Officer -
Sharon E. Underberg,
Exec. VP, Gen. Counsel, & Corp. Sec. -
Lawrence Kingsley,
Independent Chairman of the Board -
M. Anne Szostak,
Independent Director -
Daniel Junius,
Independent Director -
Bruce Claflin,
Independent Director -
Rebecca Henderson,
Independent Director -
Sophie Vandebroek,
Independent Director -
Stuart Essig,
Independent Director -
Sam Samad,
Independent Director -
Jonathan W. Ayers,
Sr. Advisor & Director -
Asha Collins,
Independent Director -
James Polewaczyk,
Executive Vice President and Chief Commercial Officer -
Tina Hunt,
Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations -
Dr. Martin Smith Ph.D.,
Exec. VP & CTO -
Ken Grady,
Sr. VP & Chief Information Officer -
Martin Smith,
Exec. VP & CTO -
Jeffery D. Chadbourne,
Sr. Director of Accounting & Financial Reporting -
John Hart,
Sr. VP of Worldwide Operations -
Barry C Johnson,
Director -
Thomas Craig,
Director -
William End,
Director -
Jacqueline Studer,
CVP, Gen. Counsel & Secretary -
Thomas J Dupree,
Corporate Vice President -
Michael J Williams,
Corporate Vice President -
Daniel V Meyaard,
Corporate Vice President -
Conan R Deady,
Vice President and Secretary -
Joseph V Vumbacco,
Director -
William E Iii Brown,
Corporate Vice President -
William B. Goodspeed,
Corporate Vice President -
Robert J Murray,
Director -
Jeffrey Fiarman,
EVP, GEN COUNSEL & SECRETARY -
Ali Naqui,
Vice President -
Johnny D Powers,
Corporate Vice President -
Errol B Desouza,
Director -
William C Wallen,
SVP & Chief Scientific Officer -
Quentin J Tonelli,
Vice President -
S Sam Fratoni,
Vice President -
Irene C Kerr,
Corporate Vice President -
Robert S Hulsy,
Vice President -
Laurel E Labauve,
Vice President -
Merilee Raines,
Vice President,CFO & Treasurer -
James L Jr Moody,
Director -
Jennifer A Joiner,
Corp VP CAG N American CommOps -
Louis W Pollock,
Senior Vice President -
Erwin R Jr Workman,
Executive Vice President -
Nimrata Hunt,
Executive Vice President -
Irene Chang Britt,
Director -
Martin Alexander Smith,
Executive Vice President -
Michael Perkins Johnson,
EVP and CHRO -
George Fennell,
SVP, Chief Revenue Officer -
Michael G Erickson,
Executive Vice President -
Michael Schreck,
Executive Vice President